Literature DB >> 15297163

The serine protease stratum corneum chymotryptic enzyme (kallikrein 7) is highly overexpressed in squamous cervical cancer cells.

Alessandro D Santin1, Stefania Cane', Stefania Bellone, Eliana Bignotti, Michela Palmieri, Luis E De Las Casas, Juan J Roman, Simone Anfossi, Timothy O'Brien, Sergio Pecorelli.   

Abstract

OBJECTIVE: To determine whether the Stratum Corneum Chymotryptic Enzyme (SCCE), a novel serine protease known to contribute to the cell shedding process by catalyzing the degradation of intercellular cohesive structures at the skin surface, is overexpressed in human cervical tumors.
METHODS: SCCE expression was evaluated in 18 cervical cancer cell lines (i.e., 10 primary and 8 established cell lines) as well as in 8 normal cervical keratinocyte cultures by RT-PCR. In addition, SCCE expression was evaluated by immunohistochemistry on paraffin-embedded tumor tissue.
RESULTS: Normal cervical keratinocytes did not express SCCE. In contrast, 50% of the primary and 50% of the established cervical cancer cell lines expressed SCCE by RT-PCR. Eighty percent (i.e., four of five) of primary squamous cervical tumors and 20% (i.e., one of five) of primary adenocarcinomas expressed SCCE. Five out of five (100%) of the patients harboring SCCE-positive tumors were found to have metastatic involvement of the pelvic tumor draining lymph nodes. Immunohistochemistry staining of paraffin-embedded cervical cancer specimens confirmed SCCE expression in tumor cells and its absence on normal cervical epithelial cells.
CONCLUSION: Squamous cervical cancer expressed high levels of SCCE, suggesting that this protease may play an important role in invasion and metastasis. Because SCCE appears only in abundance in tumor tissue and contains a secretion signal sequence, suggesting that SCCE is secreted, it may prove to be a useful diagnostic/prognostic tool for the detection of metastatic or recurrent disease or as a novel molecular target for cervical cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297163     DOI: 10.1016/j.ygyno.2004.05.023

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  7 in total

1.  Proteolytic action of kallikrein-related peptidase 7 produces unique active matrix metalloproteinase-9 lacking the C-terminal hemopexin domains.

Authors:  Vishnu C Ramani; Gur P Kaushal; Randy S Haun
Journal:  Biochim Biophys Acta       Date:  2011-05-17

2.  Serum human kallikrein 7 represents a new marker for cervical cancer.

Authors:  Weiwei Li; Yi Zhao; Lina Ren; Xin Wu
Journal:  Med Oncol       Date:  2014-09-03       Impact factor: 3.064

3.  Multiple kallikrein (KLK 5, 7, 8, and 10) expression in squamous cell carcinoma of the oral cavity.

Authors:  Jason R Pettus; Jeffrey J Johnson; Zonggao Shi; J Wade Davis; Jennifer Koblinski; Supurna Ghosh; Yueying Liu; Matthew J Ravosa; Shellaine Frazier; M Sharon Stack
Journal:  Histol Histopathol       Date:  2009-02       Impact factor: 2.303

Review 4.  Involvement of Kallikrein-Related Peptidases in Normal and Pathologic Processes.

Authors:  Ana Carolina B Stefanini; Bianca Rodrigues da Cunha; Tiago Henrique; Eloiza H Tajara
Journal:  Dis Markers       Date:  2015-12-09       Impact factor: 3.434

5.  Desmoglein 2 is a substrate of kallikrein 7 in pancreatic cancer.

Authors:  Vishnu C Ramani; Leah Hennings; Randy S Haun
Journal:  BMC Cancer       Date:  2008-12-17       Impact factor: 4.430

6.  Characterization of global transcription profile of normal and HPV-immortalized keratinocytes and their response to TNF treatment.

Authors:  Lara Termini; Enrique Boccardo; Gustavo H Esteves; Roberto Hirata; Waleska K Martins; Anna Estela L Colo; E Jordão Neves; Luisa Lina Villa; Luiz Fl Reis
Journal:  BMC Med Genomics       Date:  2008-06-27       Impact factor: 3.063

Review 7.  Emerging clinical importance of the cancer biomarkers kallikrein-related peptidases (KLK) in female and male reproductive organ malignancies.

Authors:  Manfred Schmitt; Viktor Magdolen; Feng Yang; Marion Kiechle; Jane Bayani; George M Yousef; Andreas Scorilas; Eleftherios P Diamandis; Julia Dorn
Journal:  Radiol Oncol       Date:  2013-10-08       Impact factor: 2.991

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.